ST. JUDE ELIOT: PHASE 1 EVALUATION OF LY2606368, A MOLECULARLY-TARGETED CHK1/2 INHIBITOR THERAPY, IN COMBINATION WITH CYCLOPHOSPHAMIDE OR GEMCITABINE FOR CHILDREN AND ADOLESCENTS WITH REFRACTORY OR RECURRENT GROUP 3/GROUP 4 OR SHH MEDULLOBLASTOMA BRAIN TUMORS

IND #143990
NCT#04023669

Principal Investigator
Giles W. Robinson, MD
Division of Neuro-Oncology
Department of Oncology

Co-Principal Investigator
Nicholas G. Gottardo, MB ChB, FRACP, PhD
Perth Children's Hospital
Department of Oncology and Hematology
and Telethon Kids Institute
Brain Tumor Research Program

Co-Investigators

Amar Gajjar, MD
Santhosh Upadhyaya, MD
Anna Vinitsky, MD
Greg Armstrong, MD
Ibrahim Qaddoumi, MD
Daniel Moreira, MD
Kellie Haworth, MD
Aditi Bagchi, MD
Division of Neuro-Oncology
Department of Oncology

Julie Harreld, MD
Noah Sabin, MD
Department of Diagnostic Imaging

Paul Northcott, PhD
Developmental Neurobiology

Brent Orr, MD, PhD
Department of Pathology

Clinton F. Stewart, PharmD
Department of Pharmaceutical Sciences

Martine Roussel, PhD
Department of Tumor Cell Biology

Arzu Onar-Thomas, PhD
Department of Biostatistics

Collaborating Investigators/Institutions:

Raelene Endersby, PhD
Telethon Kids Institute
Brain Tumor Research Program
Perth, Western Australia

Timothy Hassall, MD
Queensland Children's Hospital
Queensland, Australia

Jordan Hansford, MD
The Royal Children's Hospital
Melbourne, Australia

David Ziegler, MD/PhD
Sydney Children's Hospital
Sydney, Australia

ST. JUDE ELIOT: PHASE 1 EVALUATION OF LY2606368, A MOLECULARLY-TARGETED CHK1/2 INHIBITOR THERAPY, IN COMBINATION WITH CYCLOPHOSPHAMIDE OR GEMCITABINE FOR CHILDREN AND ADOLESCENTS WITH REFRACTORY OR RECURRENT GROUP 3/GROUP 4 OR SHH MEDULLOBLASTOMA BRAIN TUMORS
Principal Investigator: Giles W. Robinson, MD
Study Sponsor, United States of America: St. Jude Children's Research Hospital, *IND #143990* **Study Sponsor, Australia:** Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG)
Study Sponsor, **United States of America:** St. Jude Children's Research Hospital **Study Sponsor, Australia:** Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG)
Brief Overview: SJELIOT is a phase 1 trial that aims to explore the combination of prexasertib with established DNA-damaging agents used in medulloblastoma to evaluate tolerance and pharmacokinetics in recurrent or refractory disease. Additionally, a small expansion cohort will be incorporated into the trial at the combination MTD/RP2D (maximum tolerated dose/recommended phase two dose) to detect a preliminary efficacy signal.
Intervention: Participants will be stratified by the biological characteristics of their tumor to one of two treatment strata: • Prexasertib (LY2606368) and Cyclophosphamide (CPA) • Prexasertib (LY2606368) and Gemcitabine (GEM)
Brief Outline of Treatment Plan: Participants will receive doublet therapy in cycles of 28 days. The DLT-evaluation period will consist of the first cycle until day 1 criteria of cycle 2 has been met. Participants will be evaluated at least once a week during the DLT-evaluation period and at regular intervals thereafter. Standard tests (i.e. physical exams, blood tests, and disease evaluations) will be undertaken at regular intervals. Research-associated evaluations (i.e. pharmacokinetic studies, etc.) will also be carried out during therapy. Treatment may be continued for up to 2 years in the absence of disease progression or unacceptable toxicity.
Study Design: This is a phase I, open-label, limited dose escalation clinical trial to define the MTD/RP2D of the doublet therapies with an early expansion cohort to assess preliminary efficacy.
Sample Size: Up to 100 participants will be enrolled on this study.
Data Management: Data management and statistical analysis will be provided locally by the St Jude Comprehensive Cancer Center Neurobiology & Brain Tumor Program and the Biostatistics Department at St. Jude Children's Research Hospital.
Human Subjects: The main risk to research participants will be the potential toxicities associated with the study agents LY2606368 (Prexasertib), Cyclophosphamide, and Gemcitabine. Participants will be informed of toxicities associated with the study drug and potential side effects of procedures recommended in this study. Adverse events will be monitored, treated, and reported following institutional and federal guidelines and regulations.

ST. JUDE ELIOT: PHASE 1 EVALUATION OF LY2606368, A MOLECULARLY-TARGETED CHK1/2 INHIBITOR THERAPY, IN COMBINATION WITH CYCLOPHOSPHAMIDE OR GEMCITABINE FOR CHILDREN AND ADOLESCENTS WITH REFRACTORY OR RECURRENT GROUP 3/GROUP 4 OR SHH MEDULLOBLASTOMA BRAIN TUMORS

Due to contractual obligations with the international sponsor we are unable to provide the full protocol document.

More information about the trial can be found on the Australian New Zealand Clinical Trials Registry (anzctr.org.au) under record number NCT04023669.

Please contact the office of the Australian and New Zealand Children's Haematology / Oncology Group (ANZCHOG) for further details. Email: info@anzchog.org

ANZCHOG